Novartis’s Fevipiprant Hit By Phase III Asthma Failure

ZEAL Studies Miss Efficacy In Moderate Disease

 
• By Eleanor Malone
  
Failed launch
Novartis's fevipiprant fails to fly in moderate asthma
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Respiratory

More from Therapy Areas